Taken together, these results indicate that low NOXA expression associates with a protective effect of MCL-1 to mediate venetoclax resistance in SS, and this protection can be reversed via pharmaceutical MCL-1 inhibition. This evidence concerns the gene PMAIP1 and synovial sarcoma.